The last 5 yr have witnessed major progress in skeleton biology. One of these areas of progress has been the partial elucidation of the transcriptional mechanisms of osteoblast differentiation and their conservation between mouse and human. Cbfal, or runx2, a homolog of the Drosophila Runt protein serves both as the earliest transcriptional regulator of osteoblast differentiation and as controller of bone formation by already differentiated osteoblast. Moreover, Cbfal is also a hypertrophic chondrocyte differentiation factor in several skeletal elements. Although other transcription factors are likely to be involved in osteoblast differentiation, Cbfal, by the multiplicity of the role that it plays, can be viewed as the central regulator of intramembranous and endochondral ossification. (Endocrinology 142: [2731][2732][2733] 2001) T HE MOLECULAR UNDERSTANDING of the embryonic development and of the physiology of the skeleton has been completely renewed in the last 5 yr. Up until the early mid 1990s the only class of regulatory proteins that were known to affect skeleton biology were the bone morphogenetic proteins, and the main structural proteins to which functions were assigned were collagens. This has completely changed through the progress of mouse genetics and to a large extent of human genetics. We know now of many more genes encoding either circulating molecules or transcription factors that control patterning of the skeleton, differentiation of the three specific cell types of the skeleton and/or the functions of these cells. These three specific cell types are the chondrocytes in cartilage, the osteoblasts or bone forming cells, and the osteoclast or bone-resorbing cells in bone. This review will focus on only one cell type the osteoblast, a bone forming cell, and only transcriptional regulation of cell differentiation and function. However, as the field develops it has become clear that at least one transcription factor controls cell differentiation in both osteoblast and chondrocyte lineages and therefore we will touch upon chondrocyte differentiation as well.
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Interaction between Chondrocyte and Osteoblast Differentiation during Endochondral Ossification
Except for the clavicles and some bones of the skull that develop without a cartilage template through a process called intramembranous ossification, all the other bones develop through a process called endochondral ossification, which does make use of a cartilage template (1) . Beyond differentiation of mesenchymal cells into proliferating chondrocytes in each mesenchymal condensation prefiguring the future skeleton, there are three key events occurring late during endochondral ossification. There is first hypertrophy of chondrocytes, a process finely controlled by several growth factors (2) (3) (4) . Hypertrophic chondrocytes are surrounded by a calcified extracellular matrix rich in type X collagen that, through unknown mechanisms, favors the second key event of endochondral ossification, which is vascular invasion from the perichondrium or bone collar (5, 6) . This vascular invasion brings in mesenchymal cells from the bone collar that will differentiate into osteoblasts secreting a type I collagen rich extracellular matrix. This is the last key cellular event during endochondral ossification. This sequence of events illustrates best the interdependence between chondrocyte hypertrophy and osteoblast differentiation for bone formation to occur. The transcriptional control of these two cellular events has been partly elucidated in the recent years.
Transcriptional Control of Osteoblast Differentiation
In theory a transcriptional activator of osteoblast differentiation should fulfill three criteria: it should be expressed in osteoblast progenitors, it should control transcription of many genes expressed in osteoblasts and it should be necessary for osteoblast differentiation in vitro and in vivo. To date there is only one transcription factor identified that fulfills all these criteria. This factor is called Cbfa1 or Runx2. For the sake of clarity we will use the name of Cbfa1 in this review because it is the name most commonly used. Although Cbfa1 plays a critical role during osteoblast differentiation and this will be the focus of this review, it should be emphasized that most likely other transcription factors fulfilling these three criteria will be identified. Cbfa1 is one of the mouse homologs of the drosophila runt protein (7) . Runt itself is the founding member of a small family of important transcription/differentiation factors that are conserved from C. elegans to human (8) . They are all characterized by a DNA binding domain called the runt domain, which is 128 amino acids long (9) . Outside the Runt domain, there is little homology between runt and lozenge, the two drosophila members of this family, and their mammalian homologues which were all cloned in the beginning of the 1990s (10) .
Although Cbfa1 was initially thought to be expressed in the thymus (7), its biologic importance lies elsewhere. From a molecular biology perspective, Cbfa1 was identified as one of the two key regulators of the osteoblast-specific expression of osteocalcin (11, 12) , the most if not the only osteoblast specific gene. Cbfa1 binds to a cis-acting element present in the osteocalcin promoter in mouse, rat, and human that is necessary and sufficient to confer osteoblast-specific expression to osteocalcin or other genes. Cbfa1 during development is initially expressed at embryonic day 12 (E12) in the mesenchymal cells present in every mesenchymal condensations prefiguring the future skeletal elements whether they form through endochondral or intramembranous ossification (12) . This expression of Cbfa1 in these cells identifies them as chondro-osteoprogenitor. Starting at E14 Cbfa1 expression becomes progressively stronger in cells of the osteoblast lineage and fades away in cells of the chondrocyte lineage as will be discussed below. To date Cbfa1 is the most specific and the earliest marker of the osteoblast lineage and certainly fulfills the first condition to be a transcriptional activator of osteoblast differentiation (12) . An interesting aspect of Cbfa1 biology that has not been fully understood yet is the fact that Cbfa1 expression precedes osteogenesis from 2-3 days. This could be explained by two mechanisms: either Cbfa1 controls the expression of other transcription factors or the function of Cbfa1 is prevented during development by posttranslational processes or binding to an inhibitory co-factor for example. The early pattern of expression of Cbfa1 contrasts with the fact that its role in regulating Osteocalcin, a late marker of the osteoblast lineage. This in fact reflects that Cbfa1 is expressed at high levels in differentiated osteoblasts in postnatal life where it does play a role (see below). More in line with the early expression of Cbfa1 during skeleton development is the observation that Cbfa1 binding sites are present in all the genes expressed in an osteoblast and whose gene products contribute to form a bone extracellular matrix. Those are the type I collagen genes, bone sialoprotein (Bsp), and Osteopontin among others (12, 13) . Cbfa1 expression is not only cellspecific but it is also induced by the bone morphogenetic proteins (12), a family of secreted proteins that play an important role at the onset of endochondral ossification (14) .
The function of Cbfa1 fulfills all the promises made by its pattern of expression. For instance, Cbfa1 does act as a differentiation factor in vitro and in vivo. Indeed, transfection of Cbfa1 expression vector in mouse primary fibroblasts or in myoblast leads to the expression of the cells of molecular markers of the osteoblast lineage such as Osteocalcin and Bone sialo protein (BSP) (12) . The differentiation function of Cbfa1 is better demonstrated in mice. Inactivation of Cbfa1 in mice prevents the appearance of osteoblast (15, 16) . As a result the animals are left with a purely cartilaginous skeleton, although as will be explained below chondrocyte differentiation is not completely normal in these mutant mice. Moreover, Otto et al. (1997) uncovered that mutant mice heterozygote for the Cbfa1 deletion had a phenotype similar to a classical mouse mutant called cleidocranial dysplasia (CCD) (17) . Cbfa1 maps at the same location as CCD and in fact the two mutations are allelic. Human genetic studies also contributed to our understanding of Cbfa1 importance during skeleton development (18, 19) . Indeed, as it is the case for mice, individuals heterozygous for deletion, missense mutation, and substitution mutation in the DNA binding domain of Cbfa1 develop cleidocranial dysplasia a skeletal dysplasia marked primarily by a delay in the suture of the fontanelle and a virtual absence of clavicles. Most of the patients with CCD have a normal bone mass suggesting that a 50% decrease in Cbfa1 expression is not sufficient to cause bone loss.
Role of Cbfa1 during chondrocyte hypertrophy
As mentioned above Cbfa1 is expressed early during development (E12.5) in a cell type with apparently the potential to become either an osteoblast or a chondrocyte. From E12 to birth, in mice, Cbfa1 expression in cartilage is restricted to prehypertrophic and hypertrophic chondrocytes (20) . The expression of Cbfa1 seems to be higher in prehypertrophic chondrocytes although this could be explained by the fact that there are more cells in the hypertrophic zone than in the hypertrophic zone. In any case, this temporal and spatial pattern of restriction is consistent with a role for Cbfa1 as an inducer of chondrocyte hypertrophy since it starts to be expressed in cells of the chondrocytic lineage before chondrocyte hypertrophy does take place. This suspicion is reinforced by the observation that in Cbfa1-deficient mice hypertrophic chondrocytes are absent in femur and humerus (21, 22) . These two skeletal elements develop before the ulna and tibia for instance that do contain hypertrophic chondrocytes in Cbfa1-deficient mice. This indicates that the absence of these cells in the humeri and femur cannot be ascribed to a mere delay in cell differentiation but rather reflect a true function of Cbfa1.
In agreement with the hypothesis that Cbfa1 could act as an inducer of chondrocyte hypertrophy, in transgenic mice expressing Cbfa1 in nonhypertrophic chondrocytes under control of the chondrocyte targeting promoter, col X, throughout development there is hypertrophic chondrocyte differentiation in skeletal elements where it normally never occurs (20) . This ectopic chondrocyte hypertrophy takes place for instance in the chondrocostal cartilage and the intervertebral discs. In turn, this ectopic chondrocyte hypertrophy led to ectopic bone formation leaving unanswered the question of whether Cbfa1 is inducing transdifferentiation of proliferating chondrocytes into osteoblasts or if instead Cbfa1 was a hypertrophic chondrocyte differentiation factor. This question was answered when the Cbfa1 transgene under the control of the col X promoter, was transferred onto a Cbfa1-deficient genetic background. Indeed, on this background the transgene restored chondrocyte hypertrophy and vascular invasion in the bones of the mutant mice but did not induce osteoblast differentiation (20) , thus establishing that Cbfa1 is also a hypertrophic chondrocyte differentiation factor. This experiment also established that there is a common regulation of osteoblast and chondrocyte differentiation and that Cbfa1 is one of the genes involved in this regulation.
Transcriptional control of osteoblast function
The main function of the osteoblast throughout life is to produce a bone extracellular matrix. This process, also called bone formation, is obviously important for longitudinal growth but also to maintain a constant bone mass through bone remodeling, the process by which bone constantly re-news itself during adulthood. Cbfa1 is also involved in this cellular physiology aspect of bone biology. The DNA binding domain of Cbfa1 has no transactivation function but has a higher affinity for DNA than Cbfa1 itself, a feature seen in other members of the runt-related family of transcription factors (23) (24) (25) . In transgenic mice overexpression of this transcriptionally inactive form of Cbfa1 only in differentiated osteoblasts and only after birth led to a bone loss phenotype characterized by its post development and differentiation in appearance and its coexistence with a normal number of osteoblasts (24) . The postnatal expression of this dominant negative of Cbfa1 led to a down-regulation of Cbfa1 expression itself and of the expression of the genes required to produce a bone extracellular matrix (24) . This function of Cbfa1 could not be uncovered by studying mice or patients heterozygote for a Cbfa1 deletion. Thus, Cbfa1 is a transcription factor for all seasons in the life of an osteoblast. It is necessary for osteoblast differentiation and it also acts as a regulator of osteoblast function.
Before, Beyond, and Besides Cbfa1
As mentioned at the beginning of this review, it is likely that several gene products acting either positively or negatively are involved in the control of osteoblast differentiation and function. Cbfa1 expression must be induced and must be regulated, Cbfa1 itself may control the expression of other osteoblast-specific transcription factors and it is possible that other transcription factors affect osteoblast differentiation in a Cbfa1 independent manner. Given that there are several hundred skeletal elements in the body it is likely that Cbfa1 expression will be regulated by different genes in different parts of the skeleton. Several transcription factors have been suspected, based on genetic arguments, to act upstream of Cbfa1 in one linear cascade controlling osteoblast differentiation. For instance, the deletion of Msx2, a homeobox containing protein, causes severe skeletal abnormalities associated with a decrease in Cbfa1 expression (26) suggesting that it could act upstream of Cbfa1. Likewise, Bpx, another homeobox containing protein may also be involved in regulating Cbfa1 expression however this time in the prospective vertebral column (27) .
As mentioned above Cbfa1 expression precedes osteogenesis by several days. On one hand, there is to date no report of a gene whose expression is controlled by Cbfa1 and that would mediate some of its action. This does not mean that such factors do not exist. On the other hand, the observation that HoxA2 deficiency leads to ectopic Cbfa1 expression and bone formation (28) suggests the existence of a negative regulation of osteogenesis by factors that either inhibit Cbfa1 gene expression or directly interact with the Cbfa1 protein to prevent its transcriptional activity and/or stability. The first challenge that the field faces in the future is to identify all the players in the genetic cascade that include Cbfa1. The second challenge will be to determine if there is any Cbfa1-independent genetic pathway(s) involved in osteoblast differentiation and/or function.
